BSECompany Update15h ago · 4 Nov 2026, 03:14 pm
Intimation under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015 - Dispatch of Letter for Non- Email Cases
Mangalam Drugs & Organics Ltd · 532637
✦ AI Summary
Mangalam Drugs & Organics Ltd has dispatched a letter to non-email registered shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015, regarding the 53rd Annual General Meeting and Annual Report for the Financial Year 2025-26.
Analysis Scores
Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mangalam Drugs & Organics Ltd - 532637 - Intimation Under Regulation 36(1) (B) Of SEBI (LODR) Regulations, 2015- Dispatch Of Letter For Non Email Case
Attachments (1)
📄pdf
Download →
c829b900-a034-4e38-877d-0a400b65e4d2.pdf
View document text
Mangalam Drugs and Organics Limited
MANGALAM
d . Qffice
(Ri ;gigz,Bu zi lld zi sn lg,
z3 ord
/F 5lo 3o 0r,
/2 839
8P 7. D @’ Me 9l 1l -o
2R -o 6a 2d 6,
N 9e 0a 9r
G e5. CP.
M Lu 2Mm 4ub 2mab 3ia 0i
4 10 90
20 P0 L1
116413
WIO-T,G MP
Accredited
REF: MDOL/CS-SE/2026-27/043
November 04th, 2026
Listing Department
Listing Department
BSE Ltd
National Stock Exchange of India
I Floor, New Trade Wing,
Limited
Phiroze Jeejeebhoy Towers,
“Exchange Plaza”, 5t Floor,
Dalal Street, Fort,
Mumbai - 400 001 Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E). Mumbai — 400 051
Serip Code: 532637
Symbol: MANGALAM
Subject: I an nt di _m Da it sio cn
ou sn ud re er RR eeg qu ul ia rt ei mo en ns
s3 )0 a Rn ed
u3 l6 a( t1 i) o( nb s)
0S 1E 5B I
"( tLi hs et in Sg
O Bb Il ig La it si to in ns
Regulations™)
Dear Sir/Madam,
w amP e nu a b dr y l s i tu b hna e ekn ,t a N om it te no in c cp ld er ue o ddv oi,i n f s g w ti t ho e h en e s w 5 ei 3o xs rf ah d c R tt Ae o p ng au ni tl n uha f a t o lti r o o m Gan ects nch eea3 t rs0 ast l a h t en h M ed C e A eo3 n t6 m n i( p u1 na) a g( n l b o y) fR eh to pa hf os e rt i Ch tse ofs moS u re pE d t aB hI p neh yFyL isi tnis oact na ti cl hn i g oal se lR et e t Yg Se eu r hasl a a r rpt er 2i ho 0o ov 2n lis 5 dd, - ei 2 rna 6 sgs
aw nh do Sh ha av re
n To rt ar ne sg fi es rt e Ar ge ed nt the oi fr e t- hm ea Cil
ma pdd ar ne ys .s es with the Company or Depositories or Registrar
A copy oft he letter is enclosed herewith.
Kindly take the above and attachment provided by management on your records.
Thanking You,
Yours Faithfully,
For Mangalam Drugs & Organics Limited
Govardhan M. Dhoot
Managing Director
DIN: 01240086
Factory : at Vapi( GujaraIntd)ia & contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com
Mangalam Drugs and Organics Ltd. a—— |
Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001 -
® 91-22-22616200 / 6300 / 8787 @ 91-22-22619090 e CIN : L24230MH1972PLC116413 b g
Date: 02°¢ September, 2026
Ref:
Shareholder Name
Add 1
Add 2
Add3
Add4
Pin code:
Dear Shareholder,
Sub.: Notice of 53rd Annual General Meeting (AGM) of Mangalam Drugs and Organics Limited and Annual
Report for the Financial Year 2025-26.
We are pleased to inform you that the 53™ Annual General Meeting ('AGM') of the Members of Mangalam
Drugs and Organics Limited (‘the Company’) is scheduled to be held on Wednesday, September 23rd, 2026
at 3.00 p.m. (IST) through Video Conferencing ("VC') facility / Other Audio Visual Means ('OAVM').
As per Regulation 36 (1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
(‘SEBI Listing Regulations, 2015”), as amended, the web-link, including the exact path, where complete details
of the Annual Report are available is required to be sent to those member(s) who have not registered their email
address(es) either with the Company or with any Depository or MUFG Intime India Private Limited, Registrar
& Share Transfer Agent (RTA) of the Company.
Accordingly, the web-link, including the exact path where complete details of the Annual Report for the
Financial Year 2025-26 are available at:
Website: https://www.mangalamdrugs.com
Exact path of Annual https://www.mangalamdrugs.com/wpcontent/uploads/2026/08/mdolannualreport2026.pdf
Report 2025-26:
This letter is being sent to those member(s) who have not registered their email address(es) either with the
Company or with any Depository or RTA of the Company as on the cut-off date as on Wednesday, September
16, 2026.
This is also a reminder to update KYC details pursuant to SEBI Master Circular No. SEBVHO/MIRSD/POD-
1/P/CIR/2024/37 dated May 07, 2024, and to dematerialise physical securities. The circular issued by SEBI
mandates all the listed companies to record PAN, Address with PIN code, Mobile Number, Bank Account
details, Specimen Signature and choice of Nomination of security holders holding securities in physical mode.
‘While updating Email ID is optional, the security holders are requested to register email id also to avail online
services. This is applicable for all security holders holding securities in physical mode.
The formats for choice of Nomination and Updation of KYC details viz; Forms ISR-1, ISR-2, ISR-3,
SH-13, SH-14 and SEBI circulars are available on our website as mentioned below:
https://web.in.mpms.mufg.com/KY C-downloads.html]
The aforesaid SEBI Circular also mandates that security holders holding in physical mode whose folios do
Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com
Mangalam Drugs and Organics Ltd. a—— |
Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001 -
® 91-22-22616200 / 6300 / 8787 @ 91-22-22619090 e CIN : L24230MH1972PLC116413 b g
not have PAN, Choice of Nomination, Contact details, Bank Account details and Specimen Signature
updated, shall be eligible for any payment including dividend, interest or redemption payment in respect
of such folios, only through electronic mode with effect from April 1, 2024.
If you have any queries, please feel free to contact our RTA as details mentioned below:
MUFG Intime India Private Limited
(Formerly Link Intime India Private Limited)
Address:- C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400 083
Tel :- (+91) 8108116767
Email :- investor.helpdesk@in.mpms.mufg.com
Moreover, you are also requested to update your e mail address at the earliest either through your depository
participants for electronic holding or shares holding in physical send a communication to us / our RTA to
facilitate the updation to continue receiving all important information & documents thereafter and encourage
Green Initiative.
Thanking you,
Yours faithfully,
For Mangalam Drugs and Organics Limited
Sd/-
Shweta Patel
Company Secretary & Compliance Officer
Membership Number: A74085
3rd Floor, Rupam Bldg,
239 P D’Mello Road, Near GPO,
Mumbai — 400 001 (India).
This is a computer-generated letter, hence does not require signature
Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.mangalamdrugs.com
Page5
Dispatch No - ANNEXURE MUEG Intime, Busis ntre
Vikhroli
Name of the Licensee Oate 02:09-2026
€-101,Embassy 247, LB.S Marg, Vikhroli (West), Mumbai -400 083.
Tel. : 491 22 49186000 Fax : +91 22 4918 6060
F/M LICENCE NO. 'MH2000171/ P851079 Valuoef Unit Franked : 1ps
JCB 208294 (Sgnature of Licensee)
Franked | No. of Articles [Tota Postage
Frank Value | 18% GST et Nature of Documents Moof dDispeatcn
250 260250 1057 | AGM inbmation Leter provising web Link Leter | 2,64520 [By Oranary Post
[rovac 0.00] 2642550 1057 2642.50)
In charge, MIIPL Business, Post Centre Vikh(vWeos=l(), Mum- 4b00 a083,
Certiicate under Rules (b) o Condibon for use of Franking Machinery By Prvate Partes.
License No. : | MH2000171/PBS1078
We hereby cerify that the party mentioned herein under is our genuine cient and that the franking of Articies.
processed by us are bonafide transaction on behalf of our said cient
Name of Client Mangalam Drugs & ics Limited
Total No. of Articles 1057
Value of Postage DR P
Total Postage Value 2642.50
For MUFG Intime India Private Limited-,- ~
Head of